Cameron Health, Inc., a development stage medical device company, is creating the next generation of implantable electronic device utilizing state-of-the-art technologies. They are a team of specialized, high technology, creative individuals with decades of experience in solving difficult medical problems. Their current target is the development of a family of devices that will afford patient treatment that has been, until now, unattainable with the current therapeutic modalities and technologies.

Medtronic, Inc. operates as a medical technology company. It offers implantable cardiac pacemakers, eternal defibrillators, inferior turbinate surgery products, and continuous glucose monitoring device. The company was founded by Earl E. Bakken and Palmer J. Hermundslie on April 29, 1949 and is headquartered in Minneapolis, MN.

Cardiac Pacemakers, Inc.(CPI), doing business as Guidant Cardiac Rhythm Management, manufactured implantable cardiac rhythm management devices, such as pacemakers and defibrillators. It also sold insulin pumps controlled by microprocessors and various equipments to regulate heart rhythm. In addition, Cardiac Pacemakers, Inc. developed therapies for the treatment of irregular heartbeats. The company was founded in 1971 and is based in St. Paul, Minnesota. Cardiac Pacemakers, Inc. operates as a subsidiary of Boston Scientific Corporation.

Bard Peripheral Vascular, Inc., a subsidiary of Becton, Dickinson & Co., is an American company located in Tempe, AZ. The firm provides surgical and interventional devices for peripheral vascular patency.

pSiMedica Ltd., a subsidiary of EyePoint Pharmaceuticals, Inc., is a British company located in Malvern focused on commercial physical and biological research. The firm was founded by Sam di Giacomo. Roger Aston is currently the CEO of the company. On August 05, 2004 EyePoint Pharmaceuticals, Inc. acquired pSiMedica Ltd. for $40.97 million.

Titan Pharmaceuticals, Inc. is a biopharmaceutical Company developing proprietary therapeutics primarily for the treatment of serious medical disorders. Titan’s principal asset is Probuphine®, the first slow-release implant formulation of buprenorphine hydrochloride (“buprenorphine”), designed to maintain a stable, round-the-clock blood level of the medicine in patients for up to six months following a single treatment. The outpatient treatment of opioid dependence with daily dosed sublingual buprenorphine formulations represents a $1.3 billion market in the U.S., and a seven day transdermal patch formulation of buprenorphine for the treatment of chronic pain was launched in the U.S. in 2011. This novel implant formulation is inserted subdermally in a patient’s upper arm providing continuous medication, and has the potential to enhance patient compliance to treatment, and limit diversion for illicit use and accidental exposure to the sublingual formulations. The New Drug Application (NDA) was submitted to the FDA in October, 2012 seeking approval for treatment of opioid dependence. In December 2012, Titan entered into a license agreement with Braeburn Pharmaceuticals Sprl (“Braeburn”) that grants Braeburn exclusive commercialization rights to Probuphine® in the United States and Canada. Titan received a non-refundable up-front license fee of $15.75 million and will receive a $50 million milestone payment upon the approval of the NDA by the FDA. Additionally, Titan will be eligible to receive up to $130 million upon achievement of specified sales milestones and up to $35 million in regulatory milestones in the event of future NDA submissions and approvals for additional indications, including chronic pain. Titan will receive tiered royalties on net sales of Probuphine ranging from the mid-teens to the low twenties. Probuphine is the first product to utilize ProNeura™, a novel, proprietary, long-term drug delivery technology. The ProNeura technology has the potential to be used in developing products for the treatment of other chronic conditions, such as Parkinson’s disease, where maintaining stable, round-the-clock blood levels of a drug can benefit the patient and improve medical outcomes. Finally, Titan is also entitled to royalty revenue of 8-10% of net sales of Fanapt® (iloperidone), an atypical antipsychotic compound being marketed in the U.S. for the treatment of schizophrenia by Novartis Pharma AG (“Novartis”) under a sub-license agreement based on a licensed U.S. patent that expires in October 2016 (does not include a possible six month pediatric extension). Substantially all of this future royalty revenue has been sold to Deerfield Management (“Deerfield”), a healthcare investment fund, in exchange for cash and debt considerations which have been used to advance the development of Probuphine and for general corporate purposes.

Vasca is a medical device company that provides technologies to improve body access for therapeutic interventions in the United States and European Union. The company develops, manufactures, and markets LifeSite, a subcutaneous device that combines a valve with cannulas, which are used for the treatment of chronic renal failure. Vasca was founded in 1996 and is based in Tewksbury, Massachusetts, United States.

Eli Lilly engages in the discovery, development, manufacture, and sale of products in the pharmaceutical products business segment. The company manufactures and distributes products through owned or leased facilities in the United States, Puerto Rico, and 25 other countries. Its products are sold in approximately 135 countries. It also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production.

PharmaSens is a focussing on the development of next-generation devices for diabetes care. Their innovative, user-friendly, patch-type devices for precise administration of insulin and for continuous glucose monitoring are designed to improve the lives of people with diabetes. These devices under broad patent protection, are extremely easy to use, painless and tubeless, and designed for low costs of manufacturing.

InCube Labs is a life sciences research lab focused on developing medical breakthroughs that dramatically improve patient outcomes. Their multi-disciplinary approach integrates traditional device technologies such as electronics, software, mechanical engineering and material science, with innovations from the pharmaceutical industry, often involving protein chemistry, pharmacology and cell biology. InCube is led by Mir Imran, an accomplished medical innovator, entrepreneur and venture capitalist, who has founded more than 20 life sciences companies and holds more than 200 patents. Many of Imran’s innovations have resulted in new standards of care, including the first FDA-approved Automatic Implantable Cardioverter Defibrillator.

Aria CV was founded in 2010 by Drs. John Scandurra and Karl Vollmers, formerly Fellows at the University of Minnesota’s Medical Devices Center. Aria has an exclusive license to certain patents from the University of Minnesota. Aria CV’s device has the potential to improve outcomes by reducing the workload on the right side of the heart.

Cardiac Science extends lives by providing the public and healthcare professionals with life-saving devices. Cardiac Science are committed to eliminating needless delays between sudden cardiac arrest (SCA) and life-saving defibrillation by ensuring automated external defibrillators (AEDs) are accessible and simple to use. Cardiac Science innovative, patented Powerheart:registered: AEDs provide assistance to SCA victims in all walks of life.Cardiac Science designs, manufactures, and markets Powerheart:registered: automated external defibrillators (AEDs) and related services that facilitate successful deployments. Cardiac Science growing list of AED placements include today's Fortune 500:registered: businesses, physician offices, schools, restaurants, malls, airports, sports fields, and other public places to combat sudden cardiac arrest (SCA), the leading cause of the death in the United States.

GlySens Incorporated is a privately held corporation devoted to developing the world’s first truly long term continuous glucose monitoring system, intended to dramatically improve the lives of people with diabetes. The GlySens fully implanted sensor—demonstrated up to 18 month lifetime in preclinical testing—wirelessly links to a convenient external receiver, designed to provide continuous, at-a-glance glucose measurement, recording, and alerts regarding hypo- and hyperglycemic glucose excursions. In contrast with other approaches that may require calibration multiple-times-per-day, system calibration checks of the GlySens sensor are designed to be required only infrequently, freeing users from the need for burdensome care and maintenance. For people living with diabetes, the GlySens implantable continuous glucose monitoring system (the GlySens ICGMTM system) is intended to provide a means for easy, unobtrusive, worry-free glucose monitoring, and empower users by providing the information they need, while freeing them to live life on their own terms. The GlySens ICGM system is currently undergoing clinical evaluation; initial human implant trials have been completed, and preparations for additional human trials are underway.

NewPace Ltd. develops a novel implantable subcutaneous string defibrillator. It is used for the prevention of cardiac arrest. The company was founded by Robert S. Fishel in 2012 and is headquartered in Caesarea, Israel.

Terumo is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare.

Gesea Biosciences, Inc. provides bioscience services. The company is headquartered in San Luis Obispo, CA.

Ivy Animal Health, Inc. provides applied research and pharmaceutical product development services. The company mainly offers animal health care products to animal health industry. It offers promotants and related delivery devices for beef cattle. Ivy Animal Health was founded in 1982 and is headquartered in Overland Park, KS

Medtronic Urinary Solutions, Inc. manufactures medical devices. The company is headquartered in Cleveland, OH.